Precision BioSciences doses first patient in CAR T cell therapy trial
Category: #health  By Nikita Chaurasia  Date: 2019-04-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

Precision BioSciences doses first patient in CAR T cell therapy trial
  • Precision is creating PBCAR0191 in partnership with Servier, a multinational pharmaceutical firm
     
  • The company believes that the patient dosed in the trial is also the first US-based clinical trial to assess an allogeneic CAR T cell therapy for NHL

The US-based genome editing firm Precision BioSciences has reportedly announced that it has successfully administered the dosage of its very first gene-edited allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate, PBCAR0191, in the Phase 1/2a clinical trial. As per trusted sources, PBCAR0191 is developed from T cells derived from donors which are then altered by utilizing the ARCUS genome editing technology of Precision.

Reportedly, the alterations are designed to create CAR T cells which specifically distinguish CD19 – a significant target in several B-cell cancers – to prevent graft-versus-host ailment. According to a press release by Precision BioSciences, the CAR T cell is being assessed in adult patients with relapsed or refractory non-Hodgkin lymphoma or as an off-the-shelf cell therapy.

The company believes that the patient dosed in the trial is also the first US-based clinical trial to assess an allogeneic CAR T cell therapy for NHL.  This open label, multi-center study of PBCAR0191 is anticipated to register a minimum of 80 patients and numerous dose level of PBCAR0191 would be investigated.

According to a press release by Precision BioSciences, the clinical sites include MD Anderson Cancer Center, Dana-Farber Cancer Institute, and Moffit Cancer Center, and City of Hope. Precision is creating PBCAR0191 in partnership with Servier, a multinational pharmaceutical firm.

For the record, the basic goal of the trial is to assess the safety of PBCAR0191 and decide upon the maximum tolerated dose. The secondary goal is to assess the anti-tumor activity of PBCAR0191.

As per reliable sources, the outcomes of the trail would be collected for up to one year.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
By Nikita Chaurasia

According to reliable sources, Massachusetts-headquartered clinical stage biopharmaceutical company, Syndax Pharmaceuticals Inc. has revealed an updated data from its Phase 1 trial of its patent axatilimab. The company will reportedly present the dat...

Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
By Nikita Chaurasia

Shares of Xiaomi Corporation, a Chinese multinational electronics company, witnessed a 7.1% drop during Hong Kong trading after the company secured USD 3.91 billion in fund raising which also included the city’s top-up placement. The company h...

Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
By Nikita Chaurasia

Israel-based leading provider of advanced solutions for cybersecurity, IoT (Internet of Things) and e-Government sectors Supercom has reportedly signed a supply agreement to deliver its PureSecurity EM (Electronic Monitoring) product suite in Wiscons...